AbbVie

AbbVie preps JAK atopic dermatitis candidate for phase 3
Fierce Biotech
Sun, 09/10/17 - 11:56 am
AbbVie
JAK inhibitors
clinical trials
atopic dermatitis
Upadacitinib
Sanofi
Regeneron
Dupixent
This Shield of Patents Protects the World’s Best-Selling Drug
Bloomberg
Fri, 09/8/17 - 09:25 am
patents
AbbVie
Humira
AbbVie adds more stellar data on ABT-494 — this time for atopic dermatitis
Endpoints
Thu, 09/7/17 - 09:46 am
AbbVie
ABT-494
atopic dermatitis
Upadacitinib
Infographic | The leaders of the global hepatitis-C market
Medical Marketing and Media
Thu, 08/31/17 - 09:27 am
hepatitis C
Gilead Sciences
Merck
AbbVie
Bristol-Myers Squibb
Pharma Stocks That Could Move On New Data
Barron's
Sat, 08/26/17 - 07:36 pm
pharma stocks
AbbVie
Bayer
Novartis
Bristol-Myers Squibb
Eli Lilly
European Society of Cardiology
Biogen, Samsung Humira copy wins EU approval
Fierce Pharma
Fri, 08/25/17 - 09:52 am
Biogen
Samsung Bioepis
Europe
Humira
AbbVie
Imraldi
biosimilars
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
Fierce Pharma
Thu, 08/17/17 - 10:36 am
patents
AbbVie
Humira
Pfizer
Lipitor
Norvasc
GSK
Advair
Sanofi
Lantus
JNJ
Remicade
AstraZeneca
Crestor
Nexium
Amgen
Neulasta
Novartis
Diovan
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
Fierce Pharma
Thu, 08/10/17 - 06:58 pm
pharma stocks
Merck
Pfizer
AbbVie
Eli Lilly
Bristol-Myers Squibb
GSK
Roche
Sanofi
Bayer
Novo Nordisk
Celgene
Biogen
AstraZeneca
AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
Marketwatch
Sun, 08/6/17 - 09:48 pm
AbbVie
hepatitis C
Mavyret
Gilead Sciences
Merck
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
Motley Fool
Sat, 08/5/17 - 09:44 am
AbbVie
Gilead Sciences
hepatitis C
Mavyret
AbbVie's new pan-genotypic hepatitis C drug Mavyret deeply underprices the competition
Fierce Pharma
Fri, 08/4/17 - 11:32 am
AbbVie
hepatitis C
Mavyret
drug pricing
J&J, AbbVie's Imbruvica breaks out of blood-cancer corner with new graft-versus-host approval
Fierce Pharma
Wed, 08/2/17 - 09:33 pm
JNJ
AbbVie
Imbruvica
graft vs host disease
FDA
AbbVie confident in strategy as Humira mints money
BioPharma Dive
Sat, 07/29/17 - 09:44 am
AbbVie
Humira
AbbVie scores surprisingly good Q2 results but pipeline worries persist
Fierce Pharma
Fri, 07/28/17 - 10:42 pm
AbbVie
earnings
Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense
Motley Fool
Thu, 07/27/17 - 09:47 am
Gilead Sciences
AbbVie
hepatitis C
reorganization
Lilly, J&J, AbbVie and WuXi help seed a regenerative medicine upstart
Endpoints
Wed, 07/26/17 - 09:49 am
Eli Lilly
JNJ
AbbVie
WuXi
regenerative medicine
Rodeo Therapeutics
AbbVie Ordered to Pay $150 Million Damages in ‘Low-T’ Trial
Bloomberg
Tue, 07/25/17 - 12:04 am
AbbVie
Androgel
low testosterone
blood clots
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
Motley Fool
Sun, 07/23/17 - 11:47 am
Biogen
aducanumab
JNJ
apalutamide
Eli Lilly
abemaciclib
AbbVie
Rova-T
Celgene
ozanimod
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
Investors Business Daily
Wed, 07/19/17 - 07:55 pm
AbbVie
Gilead Sciences
hepatitis C
Vosevi
Harvoni
Sovaldi
Epclusa
Viekira Pak
5 Big Pharma Stocks With the Best Drug Pipelines
Motley Fool
Tue, 07/18/17 - 11:32 am
Big Pharma
Roche
AstraZeneca
AbbVie
Gilead Sciences
JNJ

Pages